Tag: biopharma
Immuneel Therapeutics and Manas AI to explore potential of AI-driven frameworks...
This collaboration aims to assess how Immuneel may leverage Manas AI’s neuro-symbolic models to facilitate the ability to develop and deliver advanced treatments affordably and at scale rapidly
Zydus Lifesciences reports strong Q3 and 9M FY26 financial performance
In Q3 FY26, revenue from operations rose 30% year-on-year to ₹68,645 million, while EBITDA grew 31% to ₹18,164 million, with margins improving to 26.5%
Zydus receives USFDA Orphan Drug Designation for Desidustat to treat Sickle...
Zydus’ NCE Desidustat is a hypoxia inducible factor (HIF)-prolyl hydroxylase inhibitor (PHI) and has the potential to increase haemoglobin and red blood cell counts
CM Yogi Adityanath to pharma industry: “Come, invest, produce and receive...
The Chief Minister of Uttar Pradesh inaugurated the global congregation of investors and entrepreneurs 'Uttar Pradesh Pharma Conclave 1.0' in Lucknow on February 03, 2026
Budget FY 2026-27: Medical tourism & biopharma push to strengthen healthcare...
Higher healthcare allocation, establishment of medical tourism hubs and Biopharma Shakti programme expected to enhance patient access, research capacity and sectoral growth
Budget 2026: Industry hails focus on health, medical tourism & biopharma...
Stakeholders say the Budget’s patient-first measures, push for advanced biopharma innovation, and creation of medical tourism hubs mark a decisive step toward making India a global healthcare powerhouse
Budget 2026: OPPI calls ‘Biopharma Shakti’ India’s leap toward global leadership
The Budget’s focused push on biologics and biosimilars, backed by a dedicated biopharma innovation network, was described by Matai as positioning India strongly for the next wave of complex, high-value therapies
Analyst values Vyome’s VT-1953 at USD 1 Billion upon successful completion...
Third-party analysis estimates the total addressable U.S. market to be approximately USD 2.2 billion
Merck Healthcare R&D India unveils next-gen office in Bangalore to power...
Championing collaboration, India’s technological advances, and scientific excellence for future-ready R&D in Merck Healthcare
S&P Global upgrades Biocon Biologics credit rating to BB+
The upgrade follows Biocon’s recent equity issuance undertaken to settle the compulsorily convertible preference shares (CCPS) issued to Viatris Inc.